Nanjing Leads Biolabs Co. and Dianthus (DNTH) Therapeutics announced the first subject has been successfully dosed in the Phase 1 clinical trial of LBL-047, a potential first- and best-in-class anti-BDCA2/TACI bifunctional fusion protein developed by Leads Biolabs. Top-line results in healthy volunteers are anticipated in 2H2.6
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Dianthus price target raised to $47 from $40 at H.C. Wainwright
- Dianthus Therapeutics: Strong Financials and Promising Clinical Developments Justify Buy Rating
- Dianthus price target raised to $62 from $60 at Oppenheimer
- Dianthus Therapeutics Reports Q3 2025 Financial Results
- Dianthus Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating